BioAge Labs is a clinical-stage biopharmaceutical firm based in Richmond, California, aiming to develop innovative therapies, including their flagship drug Azelaprag for obesity.
Azelaprag is a weight loss drug that is currently in Phase 2 trials. It is designed to help manage and relieve obesity effectively.
With its initial public offering, BioAge plans to raise approximately $198 million at a price of $18 per share, aiming to support its clinical developments.
BioAge's Azelaprag will likely compete in the market against established weight loss drugs, including Zepbound and Wegovy, if it successfully completes trials.
Collection
[
|
...
]